Infections in De Novo Kidney Transplant Recipients Treated With the RANKL Inhibitor Denosumab

Abstract

This post hoc analysis reveals that treatment with denosumab to prevent bone loss in first-year kidney transplant recipients was associated with more frequent episodes of urinary tract infections, whereas other infections occurred with similar frequency in both treatment groups.